Vir Biotechnology has been granted a patent for antibodies that effectively neutralize both RABV and non-RABV lyssaviruses. The patent also covers the use of these antibodies in screening methods, as well as in the diagnosis, prevention, and treatment of RABV and non-RABV lyssavirus infections. The method involves administering the specific antibody or antigen binding fragment to a subject in need. GlobalData’s report on Vir Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Vir Biotechnology, Peptide pharmacophores was a key innovation area identified from patents. Vir Biotechnology's grant share as of September 2023 was 18%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies for preventing and treating lyssavirus infections
A recently granted patent (Publication Number: US11730813B2) describes a method for preventing and/or treating lyssavirus infections, including the rabies virus (RABV) and non-RABV lyssaviruses. The method involves administering an antibody or antigen binding fragment that neutralizes the lyssavirus infection. The antibody or fragment contains specific amino acid sequences for the heavy and light chains, as outlined in the patent.
The patent claims specify different levels of sequence identity for the heavy and light chain variable regions of the antibody or fragment. These levels range from at least 80% sequence identity to at least 99% sequence identity. The antibody or fragment can be a monoclonal antibody or a human antibody, and it can neutralize infection by RABV and at least 50% of all isolates of non-RABV lyssaviruses.
The method can be used for post-exposure prophylaxis, where the antibody or fragment is administered up to seven days after infection. It can also be used in combination with a vaccine or as the first treatment in a standard post-exposure prophylaxis scheme. The dosage of the antibody or fragment can range from 0.005 to 100 mg/kg, depending on the specific circumstances.
The patent also mentions the possibility of administering a second antibody or antigen binding fragment in addition to the first one. The second antibody or fragment has its own specific amino acid sequences and can be administered simultaneously or consecutively with the first antibody or fragment.
Overall, this patent describes a method for preventing and treating lyssavirus infections using specific antibodies or antigen binding fragments. The method offers potential options for post-exposure prophylaxis and can be used in combination with other treatments. The patent provides detailed information on the specific amino acid sequences required for the antibodies or fragments, allowing for the development of targeted therapies against lyssaviruses.
To know more about GlobalData’s detailed insights on Vir Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
